Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease.
Our initial focus is on advancing AV-101, our proprietary dry powder inhaled formulation of the drug imatinib for the treatment of PAH. AV-101, delivered using a dry powder inhaler, is designed to deliver the drug directly to diseased lung tissues while limiting systemic exposure. Oral imatinib demonstrated statistically significant improvement versus placebo on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients in an international Phase 3 trial conducted by Novartis, but was poorly tolerated due to adverse events and never approved for the treatment of PAH. Aerovate has completed a Phase 1 study in healthy volunteers and AV-101 was generally well-tolerated with no serious adverse events reported.
Aerovate has initiated a Phase 2b/3 clinical trial of AV-101. For more information, please go to clinicaltrials.gov (Identifier: NCT05036135).
February 2, 2022
Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension
Events & Presentations
- Item A
- Item B
- Item C
- Item 1
- Item 2
- Item 3